Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gynecologic oncology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: Gynecologic oncology. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2004-001103-35 Sponsor Protocol Number: NSGO -EC - 0302 Start Date*: 2004-08-20
    Sponsor Name:Nordic Society for Gynecologic Oncology
    Full Title: Exemestane in Advanced or Recurrent Endometrial Carcinoma. A multicentre non-randomized Phase II study
    Medical condition: Advanced or recurrent endometrial carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004518-32 Sponsor Protocol Number: ITIC2-2.3 Start Date*: 2013-02-13
    Sponsor Name:Medizinische Universität Wien
    Full Title: ITIC2 Trial - Topical Imiquimod versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial
    Medical condition: In this randomized controlled, multi-center trial we will investigate the non-inferiority of a topical IMQ treatment compared to surgical standard treatment in selected patients diagnosed with CIN ...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003244-76 Sponsor Protocol Number: Prot-HIPEC-Ovar-201201.7 Start Date*: 2014-07-11
    Sponsor Name:Medical University of Vienna
    Full Title: Feasibility of intraoperative hyperthermic intraperitoneal chemotherapy with carboplatin and paclitaxel in patients with advanced epithelial ovarian cancer – a combined phase I / II trial
    Medical condition: Otherwise treatment-naive patients with epithelial ovarian cancer, FIGO III - IVa
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002429-37 Sponsor Protocol Number: NSGO-EC-9501 Amendment 2 Start Date*: 2004-11-17
    Sponsor Name:Nordic Society for Gynecologic Oncology
    Full Title: A randomized trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high-risk endometrial carcinoma NSGO-EC-9501 Amendment 2.
    Medical condition: Endometrial cancer stage I-III radically operated with high-risk factors (high-grade and deep myometrial infiltration, or serous or clear cell histology) that will receive adjuvant treatment with r...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000816-14 Sponsor Protocol Number: CO-338-043 Start Date*: 2016-11-24
    Sponsor Name:Clovis Oncology, Inc.
    Full Title: Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Medical condition: Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038977 Retroperitoneal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) ES (Ongoing) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002805-36 Sponsor Protocol Number: ENGOT-OV30/NSGO Start Date*: 2017-10-23
    Sponsor Name:NSGO
    Full Title: NSGO-OV-UMB1; ENGOT-OV30: A phase II umbrella trial in patients with relapsed ovarian cancer.
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033129 Ovarian neoplasms malignant (excl germ cell) HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) FI (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2005-003357-27 Sponsor Protocol Number: 26866138-LUC-2001 Start Date*: 2006-03-29
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Multicenter, Open-Label, Study of Alimta® (pemetrexed) plus VELCADE® (bortezomib) or Alimta Alone or VELCADE alone in Subjects with Locally Advanced or Metastatic Non-Small Cell Lung ...
    Medical condition: Non Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004963-68 Sponsor Protocol Number: 26866138-LUC-2006 Start Date*: 2007-10-16
    Sponsor Name:Prof Vassilis Georgoulias
    Full Title: A Phase II, Open-Label Trial of Bortezomib (Velcade®) in Combination with Gemcitabine and Cisplatin in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
    Medical condition: First Line treatment for Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004682-40 Sponsor Protocol Number: CBYL719K12301 Start Date*: 2021-06-16
    Sponsor Name:Novartis Pharma AG
    Full Title: EPIK-O: A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single a...
    Medical condition: Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) PT (Completed) FI (Trial now transitioned) CZ (Completed) DK (Completed) SK (Completed) FR (Completed) NL (Completed) ES (Ongoing) DE (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001322-26 Sponsor Protocol Number: SOV01 Start Date*: 2013-12-02
    Sponsor Name:SOTIO a.s.
    Full Title: A randomized, open-label, three-arm, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to first line standard chemotherapy (carboplatin and paclitaxel) in women with ...
    Medical condition: epithelial ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-002326-24 Sponsor Protocol Number: ALKS4230-007 Start Date*: 2023-02-13
    Sponsor Name:Mural Oncology, Inc.
    Full Title: A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial O...
    Medical condition: Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.1 10022891 - Investigations 10080244 Peritoneal cancer index PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) PL (Completed) IT (Trial now transitioned) NO (Trial now transitioned) AT (Ongoing) LT (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002023-21 Sponsor Protocol Number: GO39942 Start Date*: 2018-08-31
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB ...
    Medical condition: Diffuse large B-cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) PT (Completed) BE (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004562-40 Sponsor Protocol Number: GOG-0146Q Start Date*: 2008-01-14
    Sponsor Name:Gynecologic Oncology Group
    Full Title: A PHASE II EVALUATION OF TOPOTECAN ADMINISTERED WEEKLY IN THE TREATMENT OF RECURRENT PLATINUM-SENSITIVE OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER
    Medical condition: Patients with recurrent ovarian, fallopian tube, or primary peritoneal cancers.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004011-37 Sponsor Protocol Number: 673-203 Start Date*: 2015-07-20
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase 2, Multicenter, Open-Label, Exploratory Biomarker Study of Talazoparib (BMN 673) Monotherapy in Patients with Recurrent or Metastatic Solid Tumors
    Medical condition: Recurrent or Metastatic Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-008336-85 Sponsor Protocol Number: MO22225 Start Date*: 2009-06-05
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A single-arm Phase II clinical study of the combination of carboplatin and weekly paclitaxel plus bevacizumab as first-line treatment in patients with epithelial ovarian cancer
    Medical condition: Epithelial ovarian cancer, fallopian tube or primary peritoneal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    9.1 10016180 Fallopian tube cancer LLT
    9.1 10061344 Peritoneal neoplasm LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) NL (Completed) GB (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022949-17 Sponsor Protocol Number: ET-D-009-10 Start Date*: 2010-10-20
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of las...
    Medical condition: Advanced ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) FI (Completed) BE (Completed) NL (Ongoing) DK (Completed) DE (Completed) ES (Completed) AT (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2013-002520-17 Sponsor Protocol Number: GOGER-01 Start Date*: 2013-11-27
    Sponsor Name:AOU di Bologna, Policlinico S.Orsola-Malpighi
    Full Title: Randomized phase II study of 3 vs 6 courses of neoadjuvant carboplatin-paclitaxel chemotherapy in stage IIIC or IV epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma
    Medical condition: neoadjuvant carboplatin-paclitaxel chemotherapy in stage IIIC or IV epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016187 Fallopian tube cancer stage IV PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068974 Peritoneal carcinoma metastatic PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016186 Fallopian tube cancer stage III PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004269-26 Sponsor Protocol Number: ENGOT-ov24-NSGO Start Date*: 2015-05-22
    Sponsor Name:Nordic Society of Gynaecological Oncology - Clinical Trial Unit
    Full Title: Niraparib versus niraparib-bevacizumab combination in Women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Part 1: AVANOVA1 - A phase I study to evaluate the saf...
    Medical condition: Women with relapsed platinum-sensitive epithelial ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061344 Peritoneal neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) SE (Completed) NO (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2013-000277-72 Sponsor Protocol Number: ARRAY-162-311 Start Date*: 2013-09-18
    Sponsor Name:Array BioPharma Inc.
    Full Title: The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or...
    Medical condition: Recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) GB (Completed) AT (Completed) BE (Completed) IT (Prematurely Ended) CZ (Completed) DE (Completed) IE (Prematurely Ended) FI (Completed) NO (Completed) NL (Completed) SE (Completed) PL (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-019525-34 Sponsor Protocol Number: MO22923 Start Date*: 2010-12-17
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: GLOBAL STUDY TO ASSESS THE ADDITION OF BEVACIZUMAB TO CARBOPLATIN AND PACLITAXEL AS FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CARCINOMA OR PRIMARY PERITONEAL CARCINOMA
    Medical condition: EPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CARCINOMA PRIMARY PERITONEAL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    12.1 10033128 Ovarian cancer LLT
    12.1 10052204 Ovarian carcinosarcoma LLT
    12.1 10016180 Fallopian tube cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SK (Completed) FR (Completed) ES (Completed) LT (Completed) AT (Completed) LV (Completed) NL (Completed) IE (Completed) SE (Completed) EE (Completed) HU (Completed) IT (Completed) BG (Completed) DK (Completed) SI (Completed) GR (Completed) PT (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 01:47:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA